In conversation with... Rosie Bradley

from Listen to The Lancet Oncology · host The Lancet

Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.

Episode metadata supplied by the publisher feed · Published Mar 1, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Rosie Bradley

0:00 4:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 4 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on March 1, 2022.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!